Novo Nordisk delivered a quarter with two competing messages. The company reported third-quarter earnings of $0.89 per share on revenue of $12.192 billion. That cleared the $0.81 consensus estimate but fell just short of the $0.90 Earnings Whisper number, a 1.1% miss against the whisper. Revenue was the cleaner win, beating the $11.39 billion consensus by 7.0% and growing 3.8% year over year. Earnings fell 12.7% from a year earlier. The bigger news was guidance. Novo raised its 2026 outlook for adjusted sales and adjusted operating profit for the third consecutive time, to a range of -2% to +2% at constant exchange rates. That is a long way from the -5% to -13% range it started the year with. The central tension is that the full-year picture keeps improving while the quarterly growth rate is cooling.

The quality of the earnings line deserves scrutiny in both directions. Adjusted operating profit jumped 27% at CER to DKK 31.7 billion. That gain was flattered by an easy comparison, since Q3 2025 absorbed DKK 9 billion of company-wide transformation costs. Reported operating profit tells a different story, falling 9% at CER to DKK 23.0 billion. The decline reflects DKK 8.7 billion of non-cash impairments:

• DKK 4.6 billion tied to ziltivekimab.
• DKK 4.1 billion for right-sizing the manufacturing network.

The call also flagged roughly DKK 3.5 billion of one-time costs in the quarter. The year-over-year earnings decline sits alongside those charges. Cash generation, meanwhile, was strong. Q3 free cash flow exceeded DKK 28 billion, and the full-year free cash flow outlook now stands at DKK 60–70 billion, up from DKK 35–45 billion at the start of the year.

Beneath the upgrade, the operating trends were mixed:

• **Overall growth:** Adjusted sales growth slowed to 4% from 7% in Q2, although Q2 had a prior-period rebate benefit.
• **US Operations:** Growth slipped to 1% from 4%.
• **International Operations:** Growth eased to 8% from 10%, and international obesity growth dropped to 24% from 37%.
• **Share erosion:** International GLP-1 volume share fell to 54% from 58%. The US Wegovy franchise's share of new-to-brand prescriptions slid to just over 50%, from about 60% in Q2 and about 65% in Q1.
• **US category:** Excluding the Medicare Bridge program, the US obesity category was roughly flat from May through October. Bridge is adding about 60,000 weekly prescriptions, and that Medicare pilot ends in late 2027.

Those are not trivial cracks for a company whose investment case rests on obesity volume.

The offset is a product cycle that is gaining traction. The Wegovy pill generated DKK 5.4 billion in Q3 sales. US cumulative prescriptions climbed from more than 2 million in Q1 to more than 8 million, and pill volume rose about 20% sequentially. The international rollout has been pulled forward to more than 20 markets by the first half of 2027, with roughly 90% oral share in the UK. The Ozempic pill is reaching a new pool of patients, with more than 60% of new prescriptions going to GLP-1-naive patients. Patient additions stayed positive, lifting the obesity patient count to 5.6 million.

The pipeline also gained support. CagriSema beat tirzepatide 5 mg on weight loss in REIMAGINE 5, with 12.4% versus 9.1%. A US decision is expected around year-end, and management is preparing for an early-2027 launch. Denecimig is slated for European launches around the turn of the year.

Bears still have legitimate ammunition. Favorable 2026 US gross-to-net effects are not expected to recur, and Q4 faces a tough comparison. Further headwinds include:

• US list-price cuts take effect January 1.
• Commercial payers and employers are pulling back on obesity coverage.
• Loss of exclusivity in Canada is intensifying.
• China faces a semaglutide loss of exclusivity in 2027.
• UK pill uptake is normalizing.
• CFO Karsten Munk Knudsen departs at year-end, and management offered only puts and takes rather than 2027 guidance.

Investors did not treat the guidance raises as a turning point. Earnings Whispers sentiment, already negative, weakened further from -0.45 to -0.61. Shares have fallen 11.4% since the open after the August report, to $42.18, and sit about 4% below the 200-day moving average of $43.99. Trend readings are mixed: price and AVWAP trends are negative, while momentum has turned positive.

The bottom line is that Novo is executing better than feared on 2026, with a stronger revenue beat, a third guidance raise and a sharply higher cash outlook. However, the forward debate has shifted to 2027. Decelerating US growth, eroding share, a flat underlying US category, pricing resets and patent expirations leave the oral franchise and CagriSema carrying a heavy burden. Until management can frame next year's trajectory, the market appears inclined to discount the upgrades.